The global market for Single-Domain Antibody Therapeutics was estimated to be worth US$ 502 million in 2025 and is projected to reach US$ 1117 million, growing at a CAGR of 11.9% from 2026 to 2032. Global Market Research Publisher QYResearch (QY Research) announces the release of its latest report “Single-Domain Antibody Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on 2025 market situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Single-Domain Antibody Therapeutics market, including market size, market share, market volume, demand, industry development status, and forecasts for the next few years. The report provides advanced statistics and information on global market conditions and studies the strategic patterns adopted by renowned players across the globe. As the market is constantly changing, the report explores competition, supply and demand trends, as well as the key factors that contribute to its changing demands across many markets. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6728357/single-domain-antibody-therapeutics QYResearch has recently released the 2026 Global Single-Domain Antibody Therapeutics Market Research Report, providing a comprehensive analysis of technology platforms, market development, commercial products, clinical pipelines, competitive landscape, indication expansion, regional opportunities and industry-chain evolution. The report focuses on the growing therapeutic potential of single-domain antibody technologies, including VHH, human VH, human VL and VNAR platforms, across hematological disorders, autoimmune diseases, inflammatory conditions, oncology, respiratory diseases and infectious diseases. Single-domain antibody therapeutics represent a new generation of engineered biological medicines based on individual antibody variable domains as the core binding unit. Compared with conventional full-length monoclonal antibodies, these molecules offer smaller molecular size, enhanced tissue penetration, high structural stability, flexible engineering capabilities and compatibility with diverse biological manufacturing processes. Through molecular engineering approaches such as tandem assembly, fusion design, conjugation and multivalent construction, single-domain antibodies can be developed into monovalent, bivalent, multispecific, Fc-fusion and long-acting therapeutic formats. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 Market Size and Growth Outlook The global single-domain antibody therapeutics market was valued at approximately US$502.30 million in 2025 and is expected to reach around US$568.80 million in 2026. By 2032, the market is projected to reach approximately US$1,116.71 million, representing a CAGR of about 11.90% during 2026–2032. The market growth is driven by increasing demand for innovative biologics in areas with significant unmet medical needs, including rare hematological diseases, autoimmune disorders, refractory cancers and respiratory conditions. At the same time, advances in antibody engineering, improved manufacturing platforms and the development of next-generation delivery technologies are accelerating commercial opportunities. Future growth will increasingly depend on differentiated product strategies, including longer half-life molecules, multispecific antibody designs, targeted tissue delivery and patient-friendly administration methods such as subcutaneous and inhaled therapies. Technology Platforms and Molecular Innovation Single-domain antibody technologies mainly include VHH, human VH, human VL and VNAR platforms. Among these, VHH remains the most widely adopted technology route due to its mature discovery systems, strong stability, efficient production characteristics and broad engineering flexibility. Unlike traditional antibody structures that rely on paired heavy and light chains, single-domain antibodies utilize isolated variable domains as independent recognition units. This unique structure enables developers to create smaller and more adaptable molecules capable of accessing difficult-to-reach biological targets. Current molecular formats include: Monovalent single-domain antibodies for selective target binding and blocking functions. Bivalent and multivalent molecules designed to enhance binding strength and therapeutic activity. Multispecific antibodies capable of simultaneously regulating multiple biological pathways. Fc-fusion and albumin-binding molecules developed for improved pharmacokinetic performance and extended dosing intervals. Drug-conjugated and radionuclide-conjugated formats designed for targeted cancer therapy and precision medicine applications. The industry is moving from single-target validation toward advanced molecular architectures that provide improved efficacy, stronger differentiation and broader clinical applications. Commercial Development and Competitive Landscape The current commercial market remains highly concentrated because only a limited number of single-domain antibody therapeutics have reached commercialization. Leading companies have established competitive positions through proprietary antibody platforms, clinical development capabilities and commercialization experience. Representative global companies include Sanofi, Taisho Pharmaceutical and Alphamab Oncology. Sanofi has strengthened the commercial application of single-domain antibody technology in hematological diseases through Cablivi, targeting acquired thrombotic thrombocytopenic purpura. Taisho Pharmaceutical has expanded the application landscape in autoimmune and inflammatory diseases through Nanozora. Alphamab Oncology has advanced the commercialization of single-domain antibody technologies in cancer immunotherapy through Envafolimab, demonstrating the potential of subcutaneous administration and engineered antibody platforms. As the clinical pipeline expands, competition is shifting from basic antibody discovery toward integrated capabilities covering target selection, molecular design, clinical validation, manufacturing optimization and global commercialization partnerships. Application Areas and Market Expansion Opportunities Hematological disorders represent one of the most established application areas for single-domain antibody therapeutics. Successful clinical validation in rare blood diseases has demonstrated the ability of these molecules to achieve targeted biological effects with differentiated pharmacological characteristics. Autoimmune and inflammatory diseases represent another major growth direction. Single-domain antibodies provide opportunities for precise immune pathway regulation, improved tissue accessibility and flexible therapeutic design. Oncology is expected to become one of the largest future expansion areas. Developers are exploring immune checkpoint regulation, tumor microenvironment modulation, multispecific immune activation and antibody conjugates carrying cytotoxic or radioactive payloads. Respiratory disease applications are attracting increasing attention because of the potential advantages of molecular stability, local delivery and inhalation-based administration. Infectious disease programs are focused on rapid antigen recognition and neutralization of viral or bacterial targets. With broader clinical validation, single-domain antibodies may gradually expand from rare disease treatments into chronic diseases and larger patient populations. Regional Market Development Trends North America and Europe remain major innovation centers due to mature biotechnology ecosystems, advanced clinical trial infrastructure, strong pharmaceutical investment and established reimbursement systems for innovative therapies. Japan has strong capabilities in autoimmune disease treatment, biologics development and specialist medical channels. The commercial introduction of Nanozora has further increased awareness and clinical adoption potential for single-domain antibody products. China is emerging as a rapidly developing market driven by advances in cancer immunotherapy, biotechnology manufacturing capacity, clinical resources and engineered antibody research. The commercialization progress of Envafolimab has demonstrated the potential of domestic innovation in subcutaneous delivery, multispecific antibody development and differentiated biological therapies. Future regional growth will increasingly depend on clinical effectiveness, regulatory approval, reimbursement accessibility, pricing strategies and international cooperation models. Industry Chain Structure and Development Characteristics The upstream industry chain includes antibody discovery libraries, display technologies, target-screening platforms, engineered production cell lines, culture media, single-use bioreactor systems, chromatography materials, filtration technologies, buffers, linkers and analytical platforms. The midstream sector covers antibody discovery, affinity optimization, molecular engineering, multivalent and multispecific construction, cell-line development, process optimization, preclinical research, clinical trials, quality management, sterile filling and regulatory registration. The downstream market includes pharmaceutical companies, biotechnology enterprises, hospitals, specialist treatment centers and clinical departments such as hematology, oncology, rheumatology and respiratory medicine. The highest-value segments are concentrated in proprietary discovery platforms, molecular engineering technologies, intellectual property protection, clinical development capabilities and commercial market access. Technical Challenges and Industry Barriers Although single-domain antibody technologies demonstrate significant advantages, companies still face multiple technical and commercial challenges. Key challenges include: Developing high-quality antibody libraries and efficient screening platforms. Balancing affinity, specificity, stability and biological activity during molecular engineering. Managing aggregation risk, immunogenicity and long-term structural stability. Optimizing half-life extension strategies while maintaining therapeutic performance. Establishing consistent large-scale manufacturing processes and quality standards. Multivalent and multispecific molecules introduce additional complexity in molecular architecture, pharmacokinetic control and regulatory evaluation. Meanwhile, single-domain antibody developers must compete with conventional monoclonal antibodies, bispecific antibodies and other engineered protein therapeutics. Future Market Trends and Growth Opportunities The global single-domain antibody therapeutics market is expected to maintain strong growth momentum over the coming years. Market expansion will gradually move from a limited number of commercial products toward broader indications, diversified molecular formats and improved delivery technologies. Multivalent and multispecific antibody designs will become increasingly important for enhancing therapeutic effectiveness and product differentiation. Half-life extension technologies such as albumin binding and Fc fusion will support reduced dosing frequency and improved patient convenience. In addition, localized delivery approaches including inhalation and tissue-specific targeting may create new opportunities in respiratory and specialized disease areas. Companies with strong proprietary platforms, advanced molecular engineering capabilities, successful clinical development experience and global partnership networks are expected to achieve stronger competitive positions as the single-domain antibody therapeutics industry enters a new phase of commercialization and innovation. The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively. The Single-Domain Antibody Therapeutics market is segmented as below: By Company Sanofi Taisho Pharmaceutical Alphamab Oncology Segment by Type Cablivi Nanozora Envafolimab Segment by Application Hospital Clinic Others Each chapter of the report provides detailed information for readers to further understand the Single-Domain Antibody Therapeutics market: Chapter 1: Introduces the report scope of the Single-Domain Antibody Therapeutics report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032) Chapter 2: Detailed analysis of Single-Domain Antibody Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026) Chapter 3: Provides the analysis of various Single-Domain Antibody Therapeutics market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032) Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032) Chapter 5: Sales, revenue of Single-Domain Antibody Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032) Chapter 6: Sales, revenue of Single-Domain Antibody Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032) Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026) Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Benefits of purchasing QYResearch report: Competitive Analysis: QYResearch provides in-depth Single-Domain Antibody Therapeutics competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge. Industry Analysis: QYResearch provides Single-Domain Antibody Therapeutics comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis. and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions. Market Size: QYResearch provides Single-Domain Antibody Therapeutics market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development. Other relevant reports of QYResearch: Global Single-Domain Antibody Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032 Global Single-Domain Antibody Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032 Global Single-Domain Antibody Therapeutics Market Research Report 2026 To contact us and get this report: https://www.qyresearch.com/contact-us About Us： QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp